ClinicalTrials.gg
RecruitingNCT07850128Updated Sep 30, 2026

Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection

An observational study in Cervical Cancer Screening and HPV Infection, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to female participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Karolinska Institutet · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
130,000
Ages
22 Years to 70 Years
Sex
Female
01

Study summary

The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in HPV-based cervical screening. The main questions it aims to answer are:

  1. Whether an incident HPV detection with certain HPV genotypes has low risk of cervical cancer in 3 to 5 years thus does not need further clinical assessment before the next screening test?
  2. How risky a persistent HPV detection is, and whether persistent detection of any high-risk HPV genotype warrant immediate clinical assessment?
  3. How risky a HPV detection is, if no previous HPV test result is available?

As being a register-based retrospective observational study, study subjects will not be asked to do any specific task for this study.

Read the detailed description

This study includes all women in the study population (women at screening ages and living in the Stockholm region during 2014-2023) who had HPV positive test result(s) in the primary HPV screening. In 2014-2016, half of the screening population were randomised to primary HPV screening and the other half received cytology-based screening (NCT01511328). From 2017 onwards, all women received primary HPV screening. As data are retrieved from established registries which are already accessible to the researchers for previous and ongoing related research projects, the data collection time is almost negligible.

02

Conditions studied

  • Cervical Cancer Screening
  • HPV Infection
03

In context

Papillomavirus Infections

577 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

This study's planned enrollment of 130,000 is above the median of 486 across 159 observational studies indexed under Papillomavirus Infections.

Browse Papillomavirus Infections studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,149 studies on the registry; 277 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in the primary HPV test during 2014-2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in primary HPV test during 2014-2023

Exclusion criteria

Exclusion Criteria:

  • Women without valid personal identity number in the population registry
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
130,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Incident HPV detection

    The first HPV positive result in the primary HPV test, following an HPV negative test result in the previous primary HPV test

    Other: No Intervention: Observational Cohort

  • Persistent HPV detection

    The HPV positive result in the primary HPV test following an HPV positive test result with the same genotype in the previous primary HPV test

    Other: No Intervention: Observational Cohort

  • History-unknown HPV detection

    The first HPV positive result in the primary HPV test, without any primary HPV test record in the past

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    All data will be retrieved retrospectively from registry data.

06

What researchers measure

Primary outcomes

  1. Diagnosis of invasive cervical cancer

    Primary and invasive cervical cancer

    Time frame: From HPV infection to the end of the study Dec 31st, 2024

Secondary outcomes

  1. Precancerous lesion CIN2+ (Cervical Intraepithelial Neoplasia grade 2 and above)

    CIN2, CIN3, Adenocarcinoma in situ

    Time frame: From HPV infection to the end of the study Dec 31st, 2024

07

Study locations

1 of 1 sites recruiting
  • Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet
    Stockholm, 141 52, Sweden
    Recruiting
08

References and documents

Publications

  • Bjorge T, Stoer NC, Hverven SK, Nygard M, Trope A, Engesaeter B. Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study. Int J Cancer. 2025 Jul 15;157(2):251-259. doi: 10.1002/ijc.35359. Epub 2025 Feb 8. PubMed 39921417 ↗
  • Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024 Aug 3;404(10451):435-444. doi: 10.1016/S0140-6736(24)01097-3. PubMed 39097395 ↗

Individual participant data

Plan to share: Yes — IPD will be derived from the Swedish National Cervical Screening Registry and the Swedish National Quality Register for Gynaecological Cancers. Data from these two registries can be shared upon application, provided that ethical approval is obtained.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Nov 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Oct 31, 2025
Primary completionActual
Nov 3, 2025
CompletionEst.
Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850128
Responsible party
Jiangrong Wang (PhD, Karolinska Institutet) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 31, 2025
Primary completion
Nov 3, 2025
Completion
Dec 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Jiangrong Wang, PhD
Contact
jiangrong.wang@ki.se
+46769309451
Joakim Dillner, PhD
Contact
joakim.dillner@ki.se
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion